LXRX
Lexicon Pharmaceuticals Inc
1.80$
+0.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +333.3% | +61.0% | +45.8% | +6.3% | +1,417.4% | -95.2% | +2,187.3% | -50.9% | -61.3% | +284.2% | -96.7% | – | |
| – | +211,785.7% | -98.8% | -5.1% | -57.2% | +36,425.4% | -99.9% | +596.7% | -95.2% | +3,090.0% | -66.1% | -63.9% | – | |
| – | -9,216.1% | – | +55.1% | +13.4% | -63.0% | +98.4% | +2,226.1% | -50.5% | -63.5% | +305.8% | -96.9% | – | |
| – | -15.9% | -3.6% | +24.0% | +46.1% | +3.5% | -42.7% | +1.8% | +20.5% | -40.3% | +13.9% | +36.7% | – | |
| – | +1,258.1% | -7.8% | +22.2% | +1.0% | -18.5% | -64.0% | -19.5% | -18.7% | +15.2% | +5.4% | +5.6% | – | |
| – | -34.5% | +42.0% | +22.8% | +15.0% | -49.0% | -19.3% | -7.4% | +5.8% | -24.3% | +10.2% | +23.7% | – | |
| – | – | – | – | – | – | – | – | -426.2% | – | – | – | – | |
| – | +39.0% | -8.7% | -55.3% | +106.3% | -15.4% | -52.4% | +26.3% | -7.0% | -5.8% | -21.7% | +64.1% | – | |
| – | – | – | – | – | – | – | – | -492.7% | – | – | – | – | |
| – | -204.3% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | -492.7% | – | – | – | – | |
| – | – | – | – | – | – | – | – | -282.1% | – | – | -4,523.7% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.